Board members of LTS together with the outgoing mayor of the city of Andernach and his successor performed the groundbreaking ceremony for the future LTS Technical centre.
Advances in drugs and medical devices helping to give patients more opportunity to manage their conditions in familiar surroundings.
LTS has also responded to the SBTi’s urgent call for corporate climate action by committing to align with 1.5°C and net-zero through the Business Ambition for 1.5°C campaign.
LTS has decided to participate in an energy efficiency and climate protection network because it enables companies to plan and implement economic investments in energy efficiency on a solid data basis.
In line with recent years, 2022 was anything but plain [...]
LTS LOHMANN Therapie-Systeme AG (LTS) and Micron Biomedical, Inc. (Micron) have entered into a technical transfer and scale-up agreement for Micron´s Micro Array Patch (MAP) technology.
Get insight in the development of an Interferon-ß containing MAP (Micro Array Patch) and the performance of two prototypes in a pre-clinical study.
Dr. Michael Hoffmann was elected to succeed Oliver Hopp as a new member of the LTS Supervisory Board.
Dr. Frank Theobald verrät, wie positive Studienergebnisse, ein beschleunigter API-Screening-Service und kontinuierliche Formatinnovationen die Tür zu neuen Behandlungsmöglichkeiten mit Microarray-Pflastern öffnen.
Dr. Mike Schaefers shares his initial reflections on the company’s hybrid proposition, how it supports customer demand, and how the LTS culture keeps patient need at its core.
